Dr. Lal PathLabs Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Dr Lal PathLabs reported Q1 FY27 revenue of Rs. 798 crore, up 19.1% year-on-year, driven by patient volume growth of 8.2% and sample volume growth of 10.7%. EBITDA rose 28.7% to Rs. 247 crore with a margin of 31.0%, while profit after tax grew 27.2% to Rs. 170 crore. Management attributed part of the realization growth to CGHS/ECHS price increases and discussed rural outreach expansion, international ventures in Dubai and Ghana, and continued investment in scientific and digital initiatives.
Dr. Lal PathLabs reported Q4 FY26 revenue of Rs. 703 crore, up 16.6%, and full year FY26 revenue of Rs. 2,763 crore, up 12.2%, driven mainly by sample volume growth. EBITDA margin for the full year was 27.2%, or 28.3% excluding one-time items including a Rs. 30 crore cost related to the new Labour Code. Management discussed the acquisition of Shahbazkers Diagnostic Centre in Mumbai, continued expansion of labs and collection centres, and the launch of the Sovaaka premium wellness concept and a Dubai subsidiary for international expansion.